Uptake of third doses of SARS-CoV-2 vaccines among people with inflammatory bowel disease in Ontario, Canada.

Competing Interests: SB reports grants from the Public Health Agency of Canada. GGK has received honoraria for speaking or consultancy from AbbVie, Janssen, Pfizer, and Takeda; research support from Janssen, AbbVie, GlaxoSmithKline, Merck, and Shire; and shares ownership of a patent for treatment of inflammatory disorders, autoimmune disease, and PBC (UTI Limited Partnership, assignee. Patent 62/ 555,397). EIB has acted as a legal consultant for Hoffman La-Roche Limited and Peabody & Arnold LLP and consultant for McKesson Canada for matters unrelated to a medication used to treat inflammatory bowel disease or COVID-19. All other authors declare no competing interests. This project was supported by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Reference group and the COVID-19 Immunity Task Force. The views expressed herein do not necessarily represent the views of the Public Health Agency of Canada. The study is supported by ICES, which is funded by the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care. Parts of this material are based on data and information compiled and provided by MOH and the Canadian Institute for Health Information. The opinions, results, and conclusions reported in this paper are those of the authors and are independent of the data sources; no endorsement is intended or should be inferred. JW receives support from the Arthritis Society Stars Career Development Award (STAR-19-0610).